Detalhe da pesquisa
1.
Recent progress in the treatment of cancer in children.
CA Cancer J Clin
; 71(4): 315-332, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33793968
2.
Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia.
Blood
; 138(21): 2138-2142, 2021 11 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34499715
3.
Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns.
EClinicalMedicine
; 65: 102268, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37954907
4.
Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia.
J Clin Oncol
; 41(2): 354-363, 2023 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36108252
5.
HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL.
Blood Adv
; 7(12): 2758-2771, 2023 06 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36857419
6.
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium.
Blood Adv
; 7(4): 541-548, 2023 02 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35938863
7.
Mediport use as an acceptable standard for CAR T cell infusion.
Front Immunol
; 14: 1239132, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37965315
8.
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy.
Blood Adv
; 6(7): 1961-1968, 2022 04 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34788386
9.
Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report.
Blood Adv
; 6(2): 600-610, 2022 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34794180
10.
Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.
J Clin Oncol
; 40(9): 945-955, 2022 03 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34882493
11.
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia.
Blood Adv
; 6(14): 4251-4255, 2022 07 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-35580324
12.
Chemokine receptor CXCR4 signaling modulates the growth factor-induced cell cycle of self-renewing and multipotent neural progenitor cells.
Glia
; 59(1): 108-18, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21046557
13.
Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children's Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force.
J Clin Med
; 10(7)2021 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33915882
14.
CD19 CAR T Cells for the Treatment of Pediatric Pre-B Cell Acute Lymphoblastic Leukemia.
Paediatr Drugs
; 22(1): 1-11, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31749131
15.
Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma.
Drug Des Devel Ther
; 12: 3549-3561, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30425456